Biologic Input Output Systems

Biologic Input Output Systems

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $14.5M

Overview

BIOS is a private, pre-revenue neurotech startup pioneering a direct peripheral nerve interface to create intuitive brain-machine connections. Founded in 2018 and based in San Francisco, the company leverages implanted electrodes, advanced robotics, and AI/ML to decode and encode neural signals for prosthetic control and sensory feedback. While its primary pipeline program targets upper-limb prosthetics, the 'universal' platform has long-term potential to interface with a wide array of digital health and assistive technologies. The company appears to be in a late-development or early clinical testing stage, building upon decades of foundational academic and DARPA-funded research.

Limb Loss/Amputation

Technology Platform

Universal Neural Interface (UNI): A bidirectional, implanted peripheral nerve interface that uses electrodes, AI/ML, and robotics integration to enable motor control and sensory feedback for prosthetic limbs and potential future devices.

Funding History

2
Total raised:$14.5M
Series A$12M
Seed$2.5M

Opportunities

The immediate opportunity is to capture a premium segment of the advanced prosthetic market by solving the critical unmet need of integrated motor control and sensory feedback.
Long-term, the 'universal' platform could enable applications in neurorehabilitation, assistive tech for paralysis, and novel human-computer interfaces, tapping into the rapidly growing BCI market.

Risk Factors

Major risks include the long-term safety and stability of implanted neural interfaces, the complex and costly FDA regulatory pathway for a Class III device, and challenges in achieving insurance reimbursement for a high-cost system.
Competition from other well-funded BCI companies, both in the peripheral and central nervous system spaces, is also intense.

Competitive Landscape

BIOS competes in the advanced BCI/prosthetics space against companies like Synchron and Paradromics (focused on central BCIs), as well as established prosthetic firms (e.g., Össur, Ottobock) integrating neural interfaces. Its key differentiation is the direct peripheral nerve interface for bidirectional control, contrasting with cortical implants or surface EMG-based systems.